To advance preclinical prog in neurodegeneration
Aragen Life Sciences (Aragen), a leading Contract Research and Development Organization (CRO), and FAR Biotech (FAR), a US-based, AI-driven, computational drug discovery company, have announced a collaboration to advance preclinical programmes in neurodegeneration. As part of the collaboration, Aragen will deploy its proven experimental discovery platform to help FAR advance its small molecule programme towards an important milestone in neurodegeneration.
“We look forward to initiating our collaboration with FAR Biotech to advance its pipeline of therapeutic candidates,” said Dr Ramesh Subramanian, Chief Commercial Officer, Aragen. “Aragen has developed strong capabilities in providing integrated drug discovery (IDD) solutions to its customers to accelerate their discovery programs and this collaboration marks an inflexion point for our IDD vertical.”
Dr Simon Haydar, SVP & Head of Integrated Drug Discovery, Aragen, added, “We are encouraged by the in-silico molecules we’ve seen coming out of FAR Biotech over the past several months and look forward to helping them advance their neurodegeneration programme. We are confident that the outcome will be novel therapeutic candidates for a high-impact target that has proven hard to drug.”
Dr Martin Martinov, CEO, FAR Biotech, stated, “A key therapeutic area for FAR Biotech is neurodegeneration, where we believe our computational approach can deliver structurally diverse, novel molecules that move us closer to overcoming Alzheimer’s, Parkinson’s and other related diseases that have thus far proven intractable. We are pleased to be collaborating with Aragen – who we regard as a highly complementary expert partner that can help to accelerate our neurodegeneration programme.”